Preparation and dissolution property of ipriflavone solid dispersion

Acta Pharmacologica Sinica

Volumn 20, Issue 10, 1999, Pages 957-960

  Li, Ya Ping ^a   Zhang, Xian Ying ^a   Zhou, Jian Jun ^a   Pei, Yuan Ying ^b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Ipriflavones; Isoflavones; Pharmaceutical preparations; Polyethylene glycols; Povidone

Indexed keywords

IPRIFLAVONE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; INFRARED SPECTROSCOPY; THERMAL ANALYSIS; X RAY DIFFRACTION;

ISOFLAVONES; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 0032746334     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Kitatani K, Morii H. Ipriflavone. Nippon Rinsho 1998; 6: 1537-43.
2. Choi YK , Han IK, Yoon HK. Ipriflavone for the treatment of osteoporosis. Osteoporosis 1997; 7 Suppl 3: S174-8.
3. Avioli LV. The future of ipriflavone in the management of osteoporotic syndromes. Calcif Tissue 1997; 61 Suppl 1: S33-5.
4. Reginster JY. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner 1993; 3: 223-32.
5. Ferenc L, Istvan S. Pharmacokinetics of ipriflavone. Acta Pharm Hung 1995; 65 (6): 219-22.
6. Ferenc L, Istvan S. Metabolism of ipriflavone. Acta Pharm Hung 1995; 65 (6): 215-8.
7. Acerbi D, Poli G, Ventura P. Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes. Eur J Drug Metab Pharmacokinetic 1998; 23: 172-7.
8. Aigenis S, Zusi W, Weiketo W, inventors; Methods of preparation for inclusion compound of 7-isopropoxyisoflavone with cyclodextrin. CN patent 86 1 06839 A. 1987 July 15.
9. Yano K, Takamatsu N, Yamazaki S, Sako K, Nagura S, Tomizawa S, et al. Crystal forms, improvements of dissolution and absorption of poorly water-soluble (R)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl ]-3-(3-methylphenyl) urea (YM022). Yakugaku Zasshi 1996; 116: 8 639-46.
10. Kai T, Akiyama Y, Nomura S, Sato M. Oral absorption improvement of poorly soluble drug using solid dispersion technique. Chem Pharm Bull (Tokyo) 1996; 44: 3568-71.
11. Arias MJ, Ginés JM, Moyano JR, Rabasco AM. Dissolution properties and in vivo behavior of triamterene in solid dispersions with polyethylene glycols. Pharm Acta Helv 1996; 71: 4229-35.
12. Shargel L, Yu ABC, editors. Applied Biopharmaceutics and Pharmacokinetics. 3rd ed. New York; Appleton & Lange; 1996. p 136-7.